The Effects of Recombinant IgG4 Expression on the Growth of Sp2.0 Cell Lines

Authors
H. Jahandar
V. Khalaj
L. Nematollahi
F. Zandi
S. Enayati
B. Vaziri
Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Abstract
Objective: The study of physiological changes in recombinant cell lines provides useful information to improve production performance. In this study, we investigate the effects of an anti-CD33 chimeric IgG4 expression on Sp2.0 cell growth.
Methods: Variable region genes of light and heavy chains of monoclonal antibody produced by M195 were cloned in pFUSE-CLIg-hk and pFUSE-CHIg-hG4 expression vectors, respectively. Transfection of recombinant plasmids into Sp2.0 cell lines was performed using lipofectamine in two steps. Positive transformant cells were isolated and subjected to PCR, RT-PCR and Western blot analysis to confirm the integration of gene cassettes and the expression of recombinant IgG4.
To assess the growth parameters, recombinant and parent Sp2.0 cell lines were seeded at a density of 1×105 cells/ml in duplicate into 12-well plates. For nine days, culture plates were sampled daily and viable cell count and viability determined.
Results: The results of PCR, RT-PCR and Western blot analyses confirmed the generation of stable producer cell lines. In recombinant cells, the maximum cell density decreased by 46%. However, it was observed that IgG4 expression had no effect on cell viability of these transfectants.
Conclusion: Our results showed that the expression of recombinant IgG4 can change growth parameters in Sp2.0 cell lines that express the pFUSE-CHIg-hG4-pFUSE-CLIg-hk construct.

Keywords

[1]     Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 2005; 68(3): 283-91.
[2]     Barnes LM, Dickson AJ. Mammalian cell factories for efficient and stable protein expression. Curr Opin Biotechnol 2006; 17(4): 381-6.
[3]     Palomares LA, Estrada-Mondaca S, Ramírez OT. Production of recombinant proteins: challenges and solutions. Methods Mol Biol 2004; 267: 15-52.
[4]     Kaufmann H, Mazur X, Fussenegger M, Bailey JE. Influence of Low Temperature on Productivity, Proteome and Protein Phosphorylation of CHO Cells. Biotechnol Bioeng 1999, 63: 573-82.
[5]     Dinnis DM, James DC. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Biotechnol Bioeng 2005; 91(2): 180-9.
[6]     Glick BR. Metabolic load and heterologous gene expression. Biotechnol Adv 1995; 13(2): 247-61.
[7]     Yallop CA, Nørby PL, Jensen R, Reinbach H, Svendsen I. Characterisation of G418-induced metabolic load in recombinant CHO and BHK cells: effect on the activity and expression of central metabolic enzymes. Cytotechnology 2003; 42(2): 87-99.
[8]     Yallop CA, Svendsen I. The effects of G418 on the growth and metabolism of recombinant mammalian cell lines. Cytotechnology 2001; 35(2): 101-14.
[9]     Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 2010; 74(2): 127-38.
[10]  Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev 2006; 58(5-6): 671-85.
[11]  Chu L, Blumentals I, Maheshwari G. Production of recombinant therapeutic proteins by mammalian cells in suspension culture. In: Smales CM, James DC (Editors). Therapeutic Proteins  Methods in Molecular Biology™. Totowa: Humana Press Inc, 2005; p: 107-21.
[12]  Deyev SM, Lieber A, Radko BV, Polanovsky OL. Production of recombinant antibodies in lymphoid and non-lymphoid cells. FEBS Lett 1993; 330(2): 111-3.
[13]  Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4(4): 419-25.
[14]  Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2(1): 84-100.
[15]  Suzuki E, Ollis DF. Enhanced antibody production at slowed growth rates: experimental demonstration and a simple structured model. Biotechnol Prog 1990; 6(3): 231-6.
[16]  Bentley WE, Mirjalili N, Andersen DC, Davis RH, Kompala DS. Plasmid-encoded protein: the principal factor in the "metabolic burden" associated with recombinant bacteria. Biotechnol Bioeng 1990; 35(7): 668-81.
[17]  Betenbaugh MJ, Beaty C, Dhurjati P. Effects of plasmid amplification and recombinant gene expression on the growth kinetics of recombinant E. coli. Biotechnol Bioeng 1989; 33(11): 1425-36.
[18]  Kim SJ, Kim NS, Ryu CJ, Hong HJ, Lee GM. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 1998; 58(1): 73-84.
[19]  Pendse GJ, Karkare S, Bailey JE. Effect of cloned gene dosage on cell growth and hepatitis B surface antigen synthesis and secretion in recombinant CHO cells. Biotechnol Bioeng 1992; 40(1): 119-29.
[20]  Gu MB, Todd P, Kompala DS. Metabolic burden in recombinant CHO cells: effect ofdhfr gene amplification and lacZ expression. Cytotechnology 1995; 18(3): 159-66.
[21]  Zabriskie DW, Arcuri EJ. Factors influencing productivity of fermentations employing recombinant microorganisms. Enzyme Microb Tech 1986, 8(12): 706-17.
Pathobiology Reserach
Volume 16, Issue 4
February 2014
Pages 27-37